Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in Children With Active Moderate-to-severe Chronic Graft Versus Host Disease
NCT07116031Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Dec 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Primary endpoints: Area Under the Curve and Overall Response Rate. Started Dec 2025; status: recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07116031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116031.